CA2266640C - Methods for treating an ischemic disorder and improving stroke outcome - Google Patents

Info

Publication number

CA2266640C

CA2266640C CA2266640A CA2266640A CA2266640C CA 2266640 C CA2266640 C CA 2266640C CA 2266640 A CA2266640 A CA 2266640A CA 2266640 A CA2266640 A CA 2266640A CA 2266640 C CA2266640 C CA 2266640C

Authority

CA

Canada

Prior art keywords

stroke

selectin

cerebral

mice

surgery

Prior art date

1996-09-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 230000000302 ischemic effect Effects 0.000 title claims abstract description 91
• 238000000034 method Methods 0.000 title abstract description 91
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims abstract description 53
• 229910002091 carbon monoxide Inorganic materials 0.000 claims abstract description 53
• 208000028867 ischemia Diseases 0.000 claims description 76
• 238000001356 surgical procedure Methods 0.000 claims description 75
• 210000004556 brain Anatomy 0.000 claims description 72
• 210000002216 heart Anatomy 0.000 claims description 41
• 238000011282 treatment Methods 0.000 claims description 41
• 210000004369 blood Anatomy 0.000 claims description 33
• 239000008280 blood Substances 0.000 claims description 33
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
• 208000035475 disorder Diseases 0.000 claims description 28
• 238000002054 transplantation Methods 0.000 claims description 25
• 229910052760 oxygen Inorganic materials 0.000 claims description 18
• 239000000203 mixture Substances 0.000 claims description 16
• 230000002537 thrombolytic effect Effects 0.000 claims description 16
• 210000004072 lung Anatomy 0.000 claims description 14
• 239000001301 oxygen Substances 0.000 claims description 12
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
• 210000000056 organ Anatomy 0.000 claims description 11
• 201000010875 transient cerebral ischemia Diseases 0.000 claims description 11
• 239000008194 pharmaceutical composition Substances 0.000 claims description 10
• 239000007789 gas Substances 0.000 claims description 9
• 238000002360 preparation method Methods 0.000 claims description 8
• 208000023516 stroke disease Diseases 0.000 claims description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
• 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
• 239000011261 inert gas Substances 0.000 claims description 5
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 4
• 206010002388 Angina unstable Diseases 0.000 claims description 3
• 206010053567 Coagulopathies Diseases 0.000 claims description 3
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
• 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
• 206010050496 Reversible ischaemic neurological deficit Diseases 0.000 claims description 3
• 208000007814 Unstable Angina Diseases 0.000 claims description 3
• 206010047249 Venous thrombosis Diseases 0.000 claims description 3
• 238000012084 abdominal surgery Methods 0.000 claims description 3
• 239000003570 air Substances 0.000 claims description 3
• 230000035602 clotting Effects 0.000 claims description 3
• 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
• 210000004185 liver Anatomy 0.000 claims description 3
• 208000010125 myocardial infarction Diseases 0.000 claims description 3
• 229910052757 nitrogen Inorganic materials 0.000 claims description 3
• 210000000496 pancreas Anatomy 0.000 claims description 3
• 208000007056 sickle cell anemia Diseases 0.000 claims description 3
• 238000007631 vascular surgery Methods 0.000 claims description 3
• 229910052786 argon Inorganic materials 0.000 claims description 2
• 210000001124 body fluid Anatomy 0.000 claims description 2
• 239000010839 body fluid Substances 0.000 claims description 2
• 238000009825 accumulation Methods 0.000 abstract description 81
• 210000000265 leukocyte Anatomy 0.000 abstract description 30
• 102100022641 Coagulation factor IX Human genes 0.000 abstract description 12
• 108010076282 Factor IX Proteins 0.000 abstract description 12
• 229960004222 factor ix Drugs 0.000 abstract description 12
• 230000015271 coagulation Effects 0.000 abstract description 7
• 238000005345 coagulation Methods 0.000 abstract description 7
• 239000005557 antagonist Substances 0.000 abstract description 4
• 108010035766 P-Selectin Proteins 0.000 description 396
• 102100023472 P-selectin Human genes 0.000 description 382
• 208000006011 Stroke Diseases 0.000 description 297
• 241000699670 Mus sp. Species 0.000 description 213
• 230000010410 reperfusion Effects 0.000 description 170
• 241001465754 Metazoa Species 0.000 description 158
• 210000000440 neutrophil Anatomy 0.000 description 156
• 210000000224 granular leucocyte Anatomy 0.000 description 137
• 206010008118 cerebral infarction Diseases 0.000 description 120
• 230000014509 gene expression Effects 0.000 description 119
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 108
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 108
• 210000002889 endothelial cell Anatomy 0.000 description 107
• 238000002474 experimental method Methods 0.000 description 103
• 230000003727 cerebral blood flow Effects 0.000 description 101
• 206010061216 Infarction Diseases 0.000 description 98
• 206010008089 Cerebral artery occlusion Diseases 0.000 description 97
• 206010021143 Hypoxia Diseases 0.000 description 97
• 230000007574 infarction Effects 0.000 description 97
• 201000007309 middle cerebral artery infarction Diseases 0.000 description 97
• 230000000694 effects Effects 0.000 description 96
• 201000006474 Brain Ischemia Diseases 0.000 description 92
• 206010008120 Cerebral ischaemia Diseases 0.000 description 90
• 241000700159 Rattus Species 0.000 description 87
• 230000002490 cerebral effect Effects 0.000 description 86
• 230000035508 accumulation Effects 0.000 description 80
• 230000001965 increasing effect Effects 0.000 description 61
• 230000007954 hypoxia Effects 0.000 description 57
• 108010047303 von Willebrand Factor Proteins 0.000 description 56
• 102100036537 von Willebrand factor Human genes 0.000 description 56
• 229960001134 von willebrand factor Drugs 0.000 description 56
• 230000003447 ipsilateral effect Effects 0.000 description 51
• 238000004321 preservation Methods 0.000 description 50
• 238000005259 measurement Methods 0.000 description 49
• 238000010172 mouse model Methods 0.000 description 48
• 210000003657 middle cerebral artery Anatomy 0.000 description 47
• 230000017531 blood circulation Effects 0.000 description 42
• 230000000747 cardiac effect Effects 0.000 description 41
• 230000002631 hypothermal effect Effects 0.000 description 38
• 230000001146 hypoxic effect Effects 0.000 description 38
• 210000001519 tissue Anatomy 0.000 description 38
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
• 230000002829 reductive effect Effects 0.000 description 37
• 241000282414 Homo sapiens Species 0.000 description 35
• 150000001875 compounds Chemical class 0.000 description 35
• 241000699666 Mus <mouse, genus> Species 0.000 description 34
• PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 33
• 230000009467 reduction Effects 0.000 description 33
• 241001529936 Murinae Species 0.000 description 32
• 230000003511 endothelial effect Effects 0.000 description 32
• 230000004083 survival effect Effects 0.000 description 31
• 210000004027 cell Anatomy 0.000 description 30
• 230000001052 transient effect Effects 0.000 description 30
• 230000007971 neurological deficit Effects 0.000 description 29
• 230000000903 blocking effect Effects 0.000 description 28
• 230000007115 recruitment Effects 0.000 description 28
• 230000007246 mechanism Effects 0.000 description 27
• 108090000623 proteins and genes Proteins 0.000 description 26
• 239000000243 solution Substances 0.000 description 26
• 230000002792 vascular Effects 0.000 description 26
• 210000001772 blood platelet Anatomy 0.000 description 25
• 230000001976 improved effect Effects 0.000 description 25
• 238000010186 staining Methods 0.000 description 25
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
• 239000002953 phosphate buffered saline Substances 0.000 description 23
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 22
• 206010063837 Reperfusion injury Diseases 0.000 description 22
• 230000027455 binding Effects 0.000 description 22
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 22
• 210000004269 weibel-palade body Anatomy 0.000 description 22
• 108050006318 Haem oxygenases Proteins 0.000 description 21
• 102000016761 Haem oxygenases Human genes 0.000 description 21
• 230000002950 deficient Effects 0.000 description 19
• 102000004169 proteins and genes Human genes 0.000 description 19
• 208000026106 cerebrovascular disease Diseases 0.000 description 18
• 230000008021 deposition Effects 0.000 description 18
• 235000018102 proteins Nutrition 0.000 description 18
• 238000002560 therapeutic procedure Methods 0.000 description 18
• 230000028023 exocytosis Effects 0.000 description 17
• 230000001404 mediated effect Effects 0.000 description 17
• 239000000523 sample Substances 0.000 description 17
• 239000011780 sodium chloride Substances 0.000 description 17
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 16
• 108010054147 Hemoglobins Proteins 0.000 description 16
• 102000001554 Hemoglobins Human genes 0.000 description 16
• 108010003541 Platelet Activating Factor Proteins 0.000 description 16
• 210000003484 anatomy Anatomy 0.000 description 16
• 210000003748 coronary sinus Anatomy 0.000 description 16
• 230000001419 dependent effect Effects 0.000 description 16
• 230000001225 therapeutic effect Effects 0.000 description 16
• 241000282412 Homo Species 0.000 description 15
• 230000007423 decrease Effects 0.000 description 15
• 239000002202 Polyethylene glycol Substances 0.000 description 14
• 230000003111 delayed effect Effects 0.000 description 14
• 238000004519 manufacturing process Methods 0.000 description 14
• 230000001991 pathophysiological effect Effects 0.000 description 14
• 230000007310 pathophysiology Effects 0.000 description 14
• 229920001223 polyethylene glycol Polymers 0.000 description 14
• 206010002091 Anaesthesia Diseases 0.000 description 13
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 13
• 208000032382 Ischaemic stroke Diseases 0.000 description 13
• 241000699660 Mus musculus Species 0.000 description 13
• 208000008457 Neurologic Manifestations Diseases 0.000 description 13
• 230000037005 anaesthesia Effects 0.000 description 13
• 238000003556 assay Methods 0.000 description 13
• 210000000269 carotid artery external Anatomy 0.000 description 13
• 230000001054 cortical effect Effects 0.000 description 13
• 230000006698 induction Effects 0.000 description 13
• 230000004941 influx Effects 0.000 description 13
• 208000031225 myocardial ischemia Diseases 0.000 description 13
• 230000008506 pathogenesis Effects 0.000 description 13
• 230000004224 protection Effects 0.000 description 13
• 238000011830 transgenic mouse model Methods 0.000 description 13
• 210000005166 vasculature Anatomy 0.000 description 13
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 12
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
• 102000003800 Selectins Human genes 0.000 description 12
• 108090000184 Selectins Proteins 0.000 description 12
• 210000004004 carotid artery internal Anatomy 0.000 description 12
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 12
• 230000006378 damage Effects 0.000 description 12
• 210000003038 endothelium Anatomy 0.000 description 12
• 108020004999 messenger RNA Proteins 0.000 description 12
• 239000004677 Nylon Substances 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 239000003146 anticoagulant agent Substances 0.000 description 11
• 210000001367 artery Anatomy 0.000 description 11
• 239000011575 calcium Substances 0.000 description 11
• ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 11
• 239000007924 injection Substances 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• 238000001990 intravenous administration Methods 0.000 description 11
• 229920001778 nylon Polymers 0.000 description 11
• 230000009261 transgenic effect Effects 0.000 description 11
• 108010048049 Factor IXa Proteins 0.000 description 10
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 10
• 102100025390 Integrin beta-2 Human genes 0.000 description 10
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 10
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 10
• 208000027418 Wounds and injury Diseases 0.000 description 10
• 210000001168 carotid artery common Anatomy 0.000 description 10
• 230000004087 circulation Effects 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 230000001681 protective effect Effects 0.000 description 10
• 238000001243 protein synthesis Methods 0.000 description 10
• 208000037816 tissue injury Diseases 0.000 description 10
• 230000014616 translation Effects 0.000 description 10
• 239000003981 vehicle Substances 0.000 description 10
• 102000029816 Collagenase Human genes 0.000 description 9
• 108060005980 Collagenase Proteins 0.000 description 9
• 206010015548 Euthanasia Diseases 0.000 description 9
• 239000012981 Hank's balanced salt solution Substances 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 210000005013 brain tissue Anatomy 0.000 description 9
• 229960002424 collagenase Drugs 0.000 description 9
• 150000003278 haem Chemical class 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 239000012528 membrane Substances 0.000 description 9
• 230000000926 neurological effect Effects 0.000 description 9
• 230000037000 normothermia Effects 0.000 description 9
• 229960000187 tissue plasminogen activator Drugs 0.000 description 9
• KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 8
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
• 241000283973 Oryctolagus cuniculus Species 0.000 description 8
• 239000000427 antigen Substances 0.000 description 8
• 102000036639 antigens Human genes 0.000 description 8
• 108091007433 antigens Proteins 0.000 description 8
• 229910052791 calcium Inorganic materials 0.000 description 8
• 210000000275 circle of willis Anatomy 0.000 description 8
• 230000002939 deleterious effect Effects 0.000 description 8
• 238000003364 immunohistochemistry Methods 0.000 description 8
• 230000008595 infiltration Effects 0.000 description 8
• 238000001764 infiltration Methods 0.000 description 8
• 238000001802 infusion Methods 0.000 description 8
• 230000000977 initiatory effect Effects 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 210000001616 monocyte Anatomy 0.000 description 8
• 210000003205 muscle Anatomy 0.000 description 8
• 230000002107 myocardial effect Effects 0.000 description 8
• 230000007959 normoxia Effects 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 230000000144 pharmacologic effect Effects 0.000 description 8
• AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 8
• 229950003776 protoporphyrin Drugs 0.000 description 8
• 238000011552 rat model Methods 0.000 description 8
• 230000000007 visual effect Effects 0.000 description 8
• ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 7
• GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 7
• RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• 206010024404 Leukostasis Diseases 0.000 description 7
• 102000003896 Myeloperoxidases Human genes 0.000 description 7
• 108090000235 Myeloperoxidases Proteins 0.000 description 7
• 241000288906 Primates Species 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 7
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 7
• 238000007675 cardiac surgery Methods 0.000 description 7
• 239000003112 inhibitor Substances 0.000 description 7
• 230000033001 locomotion Effects 0.000 description 7
• 210000004379 membrane Anatomy 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 238000011002 quantification Methods 0.000 description 7
• 238000003860 storage Methods 0.000 description 7
• 210000003606 umbilical vein Anatomy 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 6
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 6
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 6
• 102000009123 Fibrin Human genes 0.000 description 6
• 108010073385 Fibrin Proteins 0.000 description 6
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
• 208000032843 Hemorrhage Diseases 0.000 description 6
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
• 102000004890 Interleukin-8 Human genes 0.000 description 6
• 108090001007 Interleukin-8 Proteins 0.000 description 6
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 238000000692 Student's t-test Methods 0.000 description 6
• 108010079274 Thrombomodulin Proteins 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 239000003963 antioxidant agent Substances 0.000 description 6
• 235000006708 antioxidants Nutrition 0.000 description 6
• 230000002612 cardiopulmonary effect Effects 0.000 description 6
• 230000015556 catabolic process Effects 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 238000011156 evaluation Methods 0.000 description 6
• 229950003499 fibrin Drugs 0.000 description 6
• 238000000760 immunoelectrophoresis Methods 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 229960003299 ketamine Drugs 0.000 description 6
• 210000004088 microvessel Anatomy 0.000 description 6
• 230000028327 secretion Effects 0.000 description 6
• 230000000451 tissue damage Effects 0.000 description 6
• 231100000827 tissue damage Toxicity 0.000 description 6
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 6
• 229960001600 xylazine Drugs 0.000 description 6
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 238000011740 C57BL/6 mouse Methods 0.000 description 5
• 241000282472 Canis lupus familiaris Species 0.000 description 5
• 206010065384 Cerebral hypoperfusion Diseases 0.000 description 5
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
• 241000282324 Felis Species 0.000 description 5
• 108010023244 Lactoperoxidase Proteins 0.000 description 5
• 102000045576 Lactoperoxidases Human genes 0.000 description 5
• 229940121825 P-selectin antagonist Drugs 0.000 description 5
• 108010023197 Streptokinase Proteins 0.000 description 5
• 102100026966 Thrombomodulin Human genes 0.000 description 5
• 208000007536 Thrombosis Diseases 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 239000011543 agarose gel Substances 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 230000002452 interceptive effect Effects 0.000 description 5
• 229940057428 lactoperoxidase Drugs 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 210000005164 penile vein Anatomy 0.000 description 5
• 210000005259 peripheral blood Anatomy 0.000 description 5
• 239000011886 peripheral blood Substances 0.000 description 5
• 230000002035 prolonged effect Effects 0.000 description 5
• 229960005202 streptokinase Drugs 0.000 description 5
• 238000011631 stroke animal model Methods 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 239000011534 wash buffer Substances 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• FUTVBRXUIKZACV-UHFFFAOYSA-L zinc;3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid Chemical compound [Zn+2].[N-]1C(C=C2C(=C(C=C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 FUTVBRXUIKZACV-UHFFFAOYSA-L 0.000 description 5
• YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 4
• JXCNUCFTHLGXDQ-UHFFFAOYSA-N 2h-tetrazol-2-ium;chloride Chemical compound Cl.C1=NN=NN1 JXCNUCFTHLGXDQ-UHFFFAOYSA-N 0.000 description 4
• 201000010000 Agranulocytosis Diseases 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 206010048964 Carotid artery occlusion Diseases 0.000 description 4
• 208000022306 Cerebral injury Diseases 0.000 description 4
• 108010024212 E-Selectin Proteins 0.000 description 4
• 102100023471 E-selectin Human genes 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 206010015866 Extravasation Diseases 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 206010058558 Hypoperfusion Diseases 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 238000000636 Northern blotting Methods 0.000 description 4
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
• 206010060872 Transplant failure Diseases 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 230000003190 augmentative effect Effects 0.000 description 4
• -1 bile acid salts Chemical class 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 229940098773 bovine serum albumin Drugs 0.000 description 4
• 239000011449 brick Substances 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 239000006229 carbon black Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 210000003710 cerebral cortex Anatomy 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 230000009089 cytolysis Effects 0.000 description 4
• 238000007405 data analysis Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 210000001671 embryonic stem cell Anatomy 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 230000036251 extravasation Effects 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 230000002055 immunohistochemical effect Effects 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
• 229940096397 interleukin-8 Drugs 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 208000037906 ischaemic injury Diseases 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 230000001473 noxious effect Effects 0.000 description 4
• 230000010412 perfusion Effects 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 230000000770 proinflammatory effect Effects 0.000 description 4
• 230000002685 pulmonary effect Effects 0.000 description 4
• 150000003254 radicals Chemical class 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 238000005096 rolling process Methods 0.000 description 4
• 210000003625 skull Anatomy 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 230000002269 spontaneous effect Effects 0.000 description 4
• 230000005945 translocation Effects 0.000 description 4
• AEGSYIKLTCZUEZ-UHFFFAOYSA-K tri(quinolin-8-yloxy)indigane Chemical compound [In+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 AEGSYIKLTCZUEZ-UHFFFAOYSA-K 0.000 description 4
• 238000005199 ultracentrifugation Methods 0.000 description 4
• 238000012800 visualization Methods 0.000 description 4
• 239000011800 void material Substances 0.000 description 4
• 108010088751 Albumins Proteins 0.000 description 3
• 102000009027 Albumins Human genes 0.000 description 3
• 206010002329 Aneurysm Diseases 0.000 description 3
• 241000282465 Canis Species 0.000 description 3
• 244000025254 Cannabis sativa Species 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 206010014498 Embolic stroke Diseases 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000004889 Interleukin-6 Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• 208000007201 Myocardial reperfusion injury Diseases 0.000 description 3
• 208000032026 No-Reflow Phenomenon Diseases 0.000 description 3
• 241000282520 Papio Species 0.000 description 3
• 240000007711 Peperomia pellucida Species 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 229940123578 Selectin antagonist Drugs 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108090000190 Thrombin Proteins 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 238000013019 agitation Methods 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 230000004872 arterial blood pressure Effects 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000003305 autocrine Effects 0.000 description 3
• 230000005540 biological transmission Effects 0.000 description 3
• 210000002459 blastocyst Anatomy 0.000 description 3
• 230000000740 bleeding effect Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 239000006227 byproduct Substances 0.000 description 3
• 210000001715 carotid artery Anatomy 0.000 description 3
• 210000004720 cerebrum Anatomy 0.000 description 3
• 230000002596 correlated effect Effects 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 230000003292 diminished effect Effects 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 108010094102 enzymobeads Proteins 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000010363 gene targeting Methods 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 210000004907 gland Anatomy 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 238000003306 harvesting Methods 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000002008 hemorrhagic effect Effects 0.000 description 3
• 230000023597 hemostasis Effects 0.000 description 3
• 229960001340 histamine Drugs 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000007654 immersion Methods 0.000 description 3
• 238000007901 in situ hybridization Methods 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 229940100601 interleukin-6 Drugs 0.000 description 3
• 230000000968 intestinal effect Effects 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 239000007928 intraperitoneal injection Substances 0.000 description 3
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
• 208000037891 myocardial injury Diseases 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 238000006386 neutralization reaction Methods 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 239000007800 oxidant agent Substances 0.000 description 3
• 230000001590 oxidative effect Effects 0.000 description 3
• 238000012335 pathological evaluation Methods 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 150000004032 porphyrins Chemical class 0.000 description 3
• 230000002980 postoperative effect Effects 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 3
• 229960003912 probucol Drugs 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 238000011555 rabbit model Methods 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 239000002412 selectin antagonist Substances 0.000 description 3
• 210000001154 skull base Anatomy 0.000 description 3
• 238000009987 spinning Methods 0.000 description 3
• 230000002459 sustained effect Effects 0.000 description 3
• 229960004072 thrombin Drugs 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
• NNVNAJGCZFCILW-UHFFFAOYSA-N 1'-methylspiro[3,4-dihydrochromene-2,4'-piperidine]-4-amine;hydrochloride Chemical compound Cl.C1CN(C)CCC21OC1=CC=CC=C1C(N)C2 NNVNAJGCZFCILW-UHFFFAOYSA-N 0.000 description 2
• 206010001526 Air embolism Diseases 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010048962 Brain oedema Diseases 0.000 description 2
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
• 102100037676 CCAAT/enhancer-binding protein zeta Human genes 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 102000002045 Endothelin Human genes 0.000 description 2
• 108050009340 Endothelin Proteins 0.000 description 2
• 108010054218 Factor VIII Proteins 0.000 description 2
• 102000001690 Factor VIII Human genes 0.000 description 2
• 108010014173 Factor X Proteins 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 206010018687 Granulocytopenia Diseases 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 102000003810 Interleukin-18 Human genes 0.000 description 2
• 108090000171 Interleukin-18 Proteins 0.000 description 2
• 108010092694 L-Selectin Proteins 0.000 description 2
• 102000016551 L-selectin Human genes 0.000 description 2
• 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 2
• 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 2
• 241001504519 Papio ursinus Species 0.000 description 2
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
• 108010000499 Thromboplastin Proteins 0.000 description 2
• 102000002262 Thromboplastin Human genes 0.000 description 2
• 108010093894 Xanthine oxidase Proteins 0.000 description 2
• 102100033220 Xanthine oxidase Human genes 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 102000019997 adhesion receptor Human genes 0.000 description 2
• 108010013985 adhesion receptor Proteins 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000008485 antagonism Effects 0.000 description 2
• 210000002551 anterior cerebral artery Anatomy 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 210000001130 astrocyte Anatomy 0.000 description 2
• 210000004227 basal ganglia Anatomy 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 208000006752 brain edema Diseases 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000003788 cerebral perfusion Effects 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 239000002975 chemoattractant Substances 0.000 description 2
• 230000001010 compromised effect Effects 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 231100000050 cytotoxic potential Toxicity 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 230000000994 depressogenic effect Effects 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 230000008497 endothelial barrier function Effects 0.000 description 2
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
• 210000003989 endothelium vascular Anatomy 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 230000005713 exacerbation Effects 0.000 description 2
• 229960000301 factor viii Drugs 0.000 description 2
• 210000004744 fore-foot Anatomy 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 244000144993 groups of animals Species 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000006702 hypoxic induction Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000003318 immunodepletion Methods 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 238000012744 immunostaining Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000005732 intercellular adhesion Effects 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 230000026045 iodination Effects 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 238000011694 lewis rat Methods 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 230000027928 long-term synaptic potentiation Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
• 229960000907 methylthioninium chloride Drugs 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 150000002772 monosaccharides Chemical class 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 230000016273 neuron death Effects 0.000 description 2
• 230000003961 neuronal insult Effects 0.000 description 2
• 239000002547 new drug Substances 0.000 description 2
• 239000002840 nitric oxide donor Substances 0.000 description 2
• 230000010417 nitric oxide pathway Effects 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 229920001542 oligosaccharide Polymers 0.000 description 2
• 150000002482 oligosaccharides Chemical class 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000008289 pathophysiological mechanism Effects 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 238000003825 pressing Methods 0.000 description 2
• 230000009862 primary prevention Effects 0.000 description 2
• 230000037452 priming Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 210000004129 prosencephalon Anatomy 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000020874 response to hypoxia Effects 0.000 description 2
• 238000000518 rheometry Methods 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 210000001913 submandibular gland Anatomy 0.000 description 2
• 230000001502 supplementing effect Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 239000003656 tris buffered saline Substances 0.000 description 2
• 238000007492 two-way ANOVA Methods 0.000 description 2
• 230000001457 vasomotor Effects 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
• CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
• BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
• 101710177959 32 kDa heat shock protein Proteins 0.000 description 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
• JBMAUZQHVVHPEL-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzenesulfonic acid Chemical compound OC1=CC=C(S(O)(=O)=O)C=C1[N+]([O-])=O JBMAUZQHVVHPEL-UHFFFAOYSA-N 0.000 description 1
• 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
• BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
• YUFCOOWNNHGGOD-UMMCILCDSA-N 8-bromo-3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br YUFCOOWNNHGGOD-UMMCILCDSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 102000055025 Adenosine deaminases Human genes 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002660 Anoxia Diseases 0.000 description 1
• 241000976983 Anoxia Species 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 208000031872 Body Remains Diseases 0.000 description 1
• 101100387911 Caenorhabditis elegans dop-2 gene Proteins 0.000 description 1
• 102000000584 Calmodulin Human genes 0.000 description 1
• 108010041952 Calmodulin Proteins 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000037823 Cerebral ischemia/reperfusion injury Diseases 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 208000001778 Coronary Occlusion Diseases 0.000 description 1
• 206010011086 Coronary artery occlusion Diseases 0.000 description 1
• 229910002535 CuZn Inorganic materials 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 229940123546 E-selectin antagonist Drugs 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010080805 Factor XIa Proteins 0.000 description 1
• 102000008857 Ferritin Human genes 0.000 description 1
• 108050000784 Ferritin Proteins 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 241000699694 Gerbillinae Species 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 101100113588 Homo sapiens CS gene Proteins 0.000 description 1
• 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 206010020565 Hyperaemia Diseases 0.000 description 1
• 102000004125 Interleukin-1alpha Human genes 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• 206010022680 Intestinal ischaemia Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• 229930064664 L-arginine Natural products 0.000 description 1
• 235000014852 L-arginine Nutrition 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 229940121930 L-selectin antagonist Drugs 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• 102000008212 P-Selectin Human genes 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 101150072307 PS gene Proteins 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
• 229920000037 Polyproline Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 101001079613 Rattus norvegicus Heme oxygenase 1 Proteins 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 208000006666 Shwartzman Phenomenon Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 208000036982 Spinal cord ischaemia Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
• 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 206010047163 Vasospasm Diseases 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000010062 adhesion mechanism Effects 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 230000003872 anastomosis Effects 0.000 description 1
• 230000007953 anoxia Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002429 anti-coagulating effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 210000000702 aorta abdominal Anatomy 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• 201000008247 brain infarction Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000001101 cardioplegic effect Effects 0.000 description 1
• 238000013216 cat model Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
• 230000004098 cellular respiration Effects 0.000 description 1
• 230000009956 central mechanism Effects 0.000 description 1
• 210000001627 cerebral artery Anatomy 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000000701 coagulant Substances 0.000 description 1
• 230000006448 coagulant property Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 201000010251 cutis laxa Diseases 0.000 description 1
• 108700042971 cyanomethemoglobin Proteins 0.000 description 1
• 229940095074 cyclic amp Drugs 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000002542 deteriorative effect Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000003617 erythrocyte membrane Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229940093476 ethylene glycol Drugs 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000003090 exacerbative effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 229940003169 factor viii / von willebrand factor Drugs 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 125000005179 haloacetyl group Chemical group 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 229940109738 hematin Drugs 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 210000003823 hyoid bone Anatomy 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 239000007925 intracardiac injection Substances 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 229940028435 intralipid Drugs 0.000 description 1
• 230000006623 intrinsic pathway Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 201000003723 learning disability Diseases 0.000 description 1
• 206010024378 leukocytosis Diseases 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000007108 local immune response Effects 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 210000001664 manubrium Anatomy 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 210000002793 maxillary artery Anatomy 0.000 description 1
• 230000015654 memory Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 210000005063 microvascular endothelium Anatomy 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• HDGCWLZQBOZSGG-UHFFFAOYSA-J molport-023-275-924 Chemical compound C1=C(N2[Sn](Cl)(Cl)N34)C(C)=C(C=C)C2=CC(=N2)C(C)=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C2C(C)=C(C=C)C1=N2 HDGCWLZQBOZSGG-UHFFFAOYSA-J 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• VTPSNRIENVXKCI-UHFFFAOYSA-N n-(2,4-dimethylphenyl)-3-hydroxynaphthalene-2-carboxamide Chemical compound CC1=CC(C)=CC=C1NC(=O)C1=CC2=CC=CC=C2C=C1O VTPSNRIENVXKCI-UHFFFAOYSA-N 0.000 description 1
• 210000002850 nasal mucosa Anatomy 0.000 description 1
• 230000001423 neocortical effect Effects 0.000 description 1
• 231100000878 neurological injury Toxicity 0.000 description 1
• 230000006764 neuronal dysfunction Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229960002460 nitroprusside Drugs 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000000082 organ preservation Substances 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 238000006303 photolysis reaction Methods 0.000 description 1
• 230000015843 photosynthesis, light reaction Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 230000009805 platelet accumulation Effects 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001987 poloxamine Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 108010026466 polyproline Proteins 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000030786 positive chemotaxis Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000003761 preservation solution Substances 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000011809 primate model Methods 0.000 description 1
• 239000011253 protective coating Substances 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 230000003331 prothrombotic effect Effects 0.000 description 1
• 210000004879 pulmonary tissue Anatomy 0.000 description 1
• 150000003222 pyridines Chemical class 0.000 description 1
• 238000004451 qualitative analysis Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 239000010453 quartz Substances 0.000 description 1
• MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 208000022064 reactive hyperemia Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 238000013376 serial cultivation Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229960000103 thrombolytic agent Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 239000012859 tissue stain Substances 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 239000008181 tonicity modifier Substances 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• PYHOFAHZHOBVGV-UHFFFAOYSA-N triazane Chemical compound NNN PYHOFAHZHOBVGV-UHFFFAOYSA-N 0.000 description 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
• 210000003954 umbilical cord Anatomy 0.000 description 1
• 238000012762 unpaired Student’s t-test Methods 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 210000001186 vagus nerve Anatomy 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 230000003966 vascular damage Effects 0.000 description 1
• 230000006492 vascular dysfunction Effects 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1